Article
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
PloS one - 27 Apr 2011
Chrisanthar Ranjan, Knappskog Stian, Løkkevik Erik, Anker Gun, Ostenstad Bjørn, Lundgren Steinar, Risberg Terje, Mjaaland Ingvil, Skjønsberg Gudbrand, Aas Turid, Schlichting Ellen, Fjösne Hans E, Nysted Arne, Lillehaug Johan Richard, Lønning Per Eystein
Abstract excerpt
BACKGROUND: TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wild-type p53 protein activity. Here, we explored the predictive and prognostic value of TP53 and CHEK2 mutation status together with MDM2 SNP309 genotype in stage III breast cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.